HONG KONG – The CFDA approved the Roche Group's Actemra (tocilizumab), which targets systemic juvenile idiopathic arthritis (sJIA). The approval marks the entry of the first biologic in the Chinese market for the disease and could lower a long-standing reliance on corticosteroids to deal with the pain of joint inflammation among children.